Chromosomal translocations, leading to gene rearrangements that generate chimerical proteins, represent one of the initiating events of leukemia. Preleukemia cells eventually develop into overt leukemia by occurrence of secondary genetic alterations (tumor progression). The physiopathology of leukemia has made considerable progress during the last two decades, due to molecular biology investigations on the role played by the altered genes, during neoplasic hemopoiesis. In vitro studies have been facilitated by the establishment of stable leukemia cell lines bearing these gene rearrangements and secondary gene mutations. Investigations on acute promyelocytic leukemia (APL) have bene®ted from maturation sensitive and resistant cell lines (NB4 and UF-1) derived from APL patient's leukemia cells and bearing the t(15;17). The information concerning the NB4 cell line (responsiveness to retinoid/rexinoid, cAMP, arsenic, mutations causing resistance) is spread in an abundant literature. In this paper, we brie¯y recapitulate the cellular and molecular features of this cell line and its subclones with the aim of facilitating investigators in their choice of the most appropriate tool for their studies. As redundancy of several names given to NB4 sublines has sometimes created diculties, we propose a nomenclature for the various NB4 sublines that most investigators certainly would be agreed with. Oncogene (2001) 20, 7287 ± 7291.
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Keywords: APL; t(15;17) cell lines; mutation; phenotypes For many years, the t(15;17) has been the karyotypic marker of Acute Promyelocytic Leukemia (APL) (Rowley et al., 1977) . The discovery of variant translocations, t(11;17)(q23;q21), t(11;17)(q13;q21), t(5;17)(q25;q21) and t(17;17), indicates that this pathology encounters diverse genetic alterations (reviewed by Melnick and Licht, 1999) . The frequency of the cases reported for each of these translocation points to t(15;17) as the most frequent cause of APL (95% of all cases). This may mean that t(15;17) occurs at the highest frequency, or else that the t(15;17) generates phenotypic modi®cations more favorable to the selection of secondary mutations and allows progression towards overt leukemia.
A common feature to these hemopoietic disorders is the alteration of RARa function by the expression of chimeric proteins, PML-RARa, PLZF-RARa, NuMaRARa, NPM-RARa and Stat5b-RARa. Two other important and common features of these disorders are the maturation-arrest of the leukemia cell at a promyelocytic stage, and a variable responsiveness to ATRA treatments allowing cell to embark on neutrophil granulocyte terminal maturation. So far, only t(15;17) cell lines have been generated from APL. This may simply re¯ect that attempts of long-term cultures of t(15;17) APL have been far more frequent than cultures of variant types, or that variant-type translocations generate a genetic environment less favorable to cell immortalization. Therefore, only t(15;17) APL has bene®ted from established cell line models for in vitro studies on the cause of promyelocyte maturation arrest and the mechanisms of retinoidinduced maturation. Note, that these two important features are not strictly speci®c to APL, since the HL60 cell line also exhibits a promyelocyte phenotype and responds to retinoic acid. The reason why this non-APL cell line shares these phenotypes with APL is not yet clear. The case of HL60 allows to speculate that genetic alterations distinct from the translocations involving RARa might also generate APL-like phenotypes. Either these events have not yet been clinically identi®ed, are mis-interpreted, or these alterations rarely end to overt leukemia and remain ignored or are treated as benign cases.
These comments point to the fact that a single cell line could not cover all the diverse aspects of a complex pathology as APL. Note that, even if a same translocation initiates the oncogenic process, the preleukemic cell developmental history by which cells progress towards overt leukemia may well dier from patient to patient. Moreover, cell lines are tools that depict some biological aspects of pathological materials which can be exploited with some bene®ts, but the many artefactual aspects of a cellular model based on a selected, immortalized tumor cell should not be neglected.
In this report, we will bring together several important biological and genetic features of the NB4 cell lines, useful to design with the best accuracy experimental in vitro protocols. A consensual nomenclature for the various NB4 sublines is proposed.
The NB4 cell line, initially . . . The NB4 cell line was isolated from long-term cultures of leukemia blast cells on bone-marrow stromal ®broblasts, as reported by Lanotte et al. (1991) . The APL patient was previously treated by classical chemotherapy and has relapsed. At the beginning, the APL blast culture showed a mixed population of ATRA-maturation sensitive and resistant cells. In an attempt to select an APL cell line, patient's cells were seeded onto pre-cultured human stromal cell feeder layers, and cultured for months. Only a minor subpopulation of leukemia cells survived in close contact to stromal cells, as few cobblestone foci. While the¯oating cell population stopped growing and died during the ®rst month, only the stroma-associated cells were maintained in culture and showed little growth during the next months. As a late event, a promyelocytic cell population emerged in the culture as an autonomously growing culture. It seems worth reminding this point, since it may indicate that the NB4 cell line corresponds to a selected subpopulation with distinct features, not re¯ecting the patient's leukemia cells. However, all cells examined for karyotype were t(15;17) positive and hypotetraploid. The NB4 cell line was responding to ATRA by granulocytic maturation. The cell line was easily cloned by limiting dilution and a homogenous ATRA-responsive, maturation responsive cell line was isolated. Nonetheless, long-term treatment with ATRA of the initially isolated NB4 cell line showed the presence of maturation-resistant cells (uncloned). A stable maturation-resistant cell line, NB4-RAr was isolated (Duprez et al., 1992) . Selection and cloning of NB4-RAr cells allowed the identi®ca-tion of two distinct maturation-resistant cell populations (Ruchaud et al., 1994) . NB4-R1, an ATRAresponsive cell line for which ATRA alone fails to induce maturation, but renders these cells competent to maturation triggering by cAMP signaling. NB4-R2, an ATRA-resistant cell line, onto which RAR-dependent priming' does not occur and let inoperative cAMP to trigger maturation. Note that in NB4-R2, ATRAunresponsiveness is associated with a point mutation in the retinoid-binding domain of PML-RARa (Duprez et al., 2000) . A ®nding of interest is that NB4-R2 is fully responsive to cross-talk between`rexinoid' and cAMP signals for maturation (Benoit et al., 1999) . In our hands, all the resistant cell lines derived from the initial NB4 isolate by this drug selection/cloning protocol, so far belonged to either the R1 or R2 phenotypes. Since the karyoptype of NB4 cell line was extremely complex and highly altered (see in Lanotte et al., 1991) , it comes with some surprise that all these cell lines shared the same gross chromosome alterations, indicating that endoploidy and chromosome alterations occurred before the immortalization of the NB4 cells. Although resistance to ATRA was obvious from clinical data, from the primary cultures before the selection of NB4, and from the earliest cultures of uncloned NB4, it remains unclear whether NB4-R1 and NB4-R2 cells features the patient's resistance to ATRA.
The NB4 cell line have been furnished to several hundred of laboratories during the last decade. During the early 90s, the NB4 cell line was provided as an ATRA-sensitive uncloned NB4 cell lines (several laboratories bene®ted from these cells, Drs C Chomienne and A Dejean (Paris), Prof P Chambon (Strasbourg); Dr E Dmitrowski (New-York); Dr Chang (Houston); Dr Z Chen (Shanghai); Dr R Evans (La Jolla); Dr PG Pelicci (Milan)). Since 1993, any of the NB4 sensitive and the resistant NB4-R1 and NB4-R2 cells we distributed, were cloned cell lines.
. . . and out of our laboratory After our publication in 1994, several laboratories have independently isolated NB4 subclones using various selection protocols sometimes preceded by mutagenesis. Great confusion has resulted from the names given to these clones; typically similarly named but distinct NB4-R1 and NB4-R2 cells were published. This has been the case for the Miller's group (Montreal) that, in 1996, has initiated a new series with the labels R1 to R10 (Rosenauer et al., 1996; Shao et al., 1997) . The confusion increased further when later on, in 1997, the Dmitrowski's group (New York) published new resistant subclones also named NB4-R1, NB4-R2, R3 and R4 (Nason-Burchenal et al., 1997 . Note that the distinct nomenclature system used by Dermime et al. (1993 Dermime et al. ( , 1995 for several retinoid-resistant cell lines (NB4-306; NB4-007/6) has so far created less problems, since no duplicated names are used so far. The Naoe's group has investigated also ATRA-resistant NB4 clones (NB4/RA) . Such aberrations justify to introduce urgently a global nomenclature to avoid misuse of the cellular and molecular NB4-derived materials. Here we are proposing a nomenclature that should receive a consensus from NB4 cell users.
An attempt to a consensus on a nomenclature of NB4 sublines

NB4 cells
First of all, the cell line was named NB4 and not NB-4. Among the near 500 papers using this cell line some 23 papers have used misleadingly, NB-4, as a name. This is detrimental to these works since these papers are not caught by computer programs when the keyword NB4' is used to screen the literature. In some cases, it may have resulted from typing errors. This has happened in some papers from several groups (H Drexler, Braunschweig; Ph Koeer, Los Angeles; C Chomienne, Paris; L Platanias, Chicago; R Larson, New Mexico; Z Chen, Shanghai). NB-4 should be immediately abandoned since an abundant literature uses this label for human and murine neuroblastoma cell lines (NB-1, NB-2, NB-3, . . . there are more than 25 distinct neuroblastoma cell lines using the NB-x nomenclature). Note that NB.4 found in some papers also should be avoided, because of the nomenclature of interneurones in the central nervous system development of Drosophila (NB.1 to NB.17). With regard to the t(15;17) promyelocytic leukemia we isolated, during the last 10 years, only the use of NB4 has created no confusion.
NB4 cells resistant to retinoid-induced maturation
The ®rst sublines derived from NB4 cells have been selected for the absence of maturation in presence of ATRA (broadly speaking RAR panagonists) for several months and when they retain resistance when cultured without retinoic acid. These cell lines should be named NB4-R. Note that the absence of the standard features of granulocytic maturation (morphology, NBT response, CD11c expression) does not indicate that NB4-R means unresponsiveness to retinoic acid signaling, unless this has been shown. For instance, the NB4-R1 cell line we have isolated exquisitely illustrates this point. NB4-R1 cells are unique in that they do respond to retinoic acid transcriptionnally, upregulate RARa, down-regulate RXR, down-regulate hTERT, degrade PML-RARa, and most important become competent for maturation (Ruchaud et al., 1994; Duprez et al., 1996a,b; Pendino et al., 2001) . Indeed, these cells do not mature in response to retinoid signaling, unless maturation is triggered by cAMP. The molecular defect(s) behind this feature have not been identi®ed yet.
Note that the ATRA maturation resistant cell lines are responsive to RXR-agonists (rexinoids) although rexinoid signaling is not self-sucient to provoke maturation and needs a signal cross-talk with cAMP (Benoit et al., 1999) . Moreover, rexinoid signaling alone can induce immature NB4 cell death by apoptosis (Benoit et al., 2001) . No resistance to rexinoid signaling has been so far reported. In case such sublines were published, one should advise authors to dierentiate them from the ATRA-maturation resistant cell lines, for example using the following names, NB4-RX1, NB4-RX2. . .
The anarchical nomenclature currently used for NB4-R subclones comes from the redundancy created by both Miller's and Dmitrovski's groups from 1996 to 1998, after our paper describing NB4-R1 and NB4-R2 (Ruchaud et al., 1994) . Given the number of papers referring to this literature on all these resistant cell lines, it seems dicult to re-name by increasing the number of all cell lines, which would possibly add confusion to confusion. A consensual position would consist to add a`letter' in front of R to identi®ed the laboratory from which the NB4 subline has been isolated. This idea seems to obtain a large agreement from many colleagues consulted. A`letter' to identify a working place has been suggested. However, it seems not the ideal solution, since most often it will not speak to readers, and furthermore people move frequently. A better solution suggested to us consists in using the last name initial of the corresponding author of the paper describing ®rst each NB4 subline. For instance, the various NB4-resistant sublines isolated by our group, Miller's, Dmitrovski's and Naoe's groups, should be re-named, NB4-LR, NB4-MR, NB4-DR and NB4-NR respectively, saving for each cell line its present number. The cell lines reported by Gambacorti's group (Dermime et al., 1993 (Dermime et al., , 1995 could ®t well in this nomenclature system (NB4-GR), as NB4-GR306 and NB4-GR007/6. However, saving their present name (NB4-306; NB4-007/6) there is little risk of confusion. In the future, authors reporting a new cell line should conform strictly to this rule.
So far, the only mutations identi®ed in ATRAresistant NB4 cell lines aected PML-RARa, into its retinoid acid ligand-binding domain (LBD). This is the case of NB4-LR2 (mutation at Gln?STOP at codon 411 of RARa, codon 913 in PML-RARa), NB4-MR4 (mutation at L-398 of RARa, codon 889 of PMLRARa) and NB4-NRA (mutation P?L at codon 407 of RARa, codon 898 of PML-RARa). Note that both the stop codon mutation at 411 in NB4-LR2, which is also the mutations found in HL60-R (Robertson et al., 1992) and UF-1 (Kizaki et al., 1999) and the missense mutation at L-398 in NB4-MR4 cause full resistance to ATRA, while the P-407 mutation of NB4-NRA confers decreased ATRA binding and a defective RA-dependent PML-RARa pathway and shares with NB4-LR1 cells the capacity to dierentiate by combining ATRA/ cAMP signals. Note that NB4-LR2 and NB4-GR-306 share undetected expression of PML-RARa by antiRARa (F115) antibodies, while the PML-RARa transcript was normally expressed in both cell lines.
Finally, as a general rule, research groups having obtained various subclones that are merely reproducing the same phenotypes should not encumber the literature with a long list of sublines; it should be realized that this would be detrimental to their own work and to the progress of the knowledge in this ®eld. Note also that, given the selection method it is not unlikely that identical sublines can be selected independently in several places (or may result from cross-contamination of cultures). When this occurs, identical cell lines should be not carried in protocols and in the literature; it is strongly advised that thè secondary' line(s) be spontaneously discarded, only the ®rst one reported being retained.
NB4 cell line transfectants
In an order to improve further the NB4 tool, several laboratories have attempted and some have succeeded in transfecting NB4 sensitive or NB4-resistant sublines with transgenes. Transfected cell lines should also conform to the above de®ned rules. The speci®cation of the transgene should follow the name of the subline. As an example, NB4-LR1/hTERT will become the identi®cation of one transfectant NB4-LR1 cell line derived from NB4-LR1 and expressing ectopic hTERT gene (Pendino et al., 2001 ).
NB4 cells resistant to arsenic induced maturation and/or apoptosis
Arsenic trioxide has been reported to induce maturation and apoptosis in NB4 cells, as well as in APL patients (Chen et al., 1996 (Chen et al., , 1997 Shen et al., 2001) . However, maturation of NB4 is often described as a late event occurring at concentrations which are borderline to those inducing cell death. Moreover, arsenic alone on NB4 cells could generate transient maturation unresponsiveness. Long-term culture of arsenic resistant cells in the absence of arsenic trioxide, often do not retain their resistance. It is not yet certain whether these cell populations should be de®ned as arsenic-resistant sublines, since they could merely re¯ect a drug adaptation, or a transient deactivation of an unknown mechanism. In the future, in term of a nomenclature of these cells, it is suggested to use the same logic: NB4-dT-AsR1, NB4-N-AsR1 and NB4-MAsR1 to name the arsenic-resistant NB4 cell lines isolated by de TheÂ 's group (Gianni et al., 1998 ), Naoe's group (Kitamura et al., 2000) and Miller's group (unpublished), respectively.
NB4 cell lines resistant to drug-induced apoptosis
Note that the NB4 cell line exhibited a relatively high resistance to several chemotherapeutical drugs. This feature should not be taken as a feature of primary APL cells, for it most likely results from selection after the successive rounds of chemotherapy delivered to this patient, after relapse. Moreover, of note is the highly abnormal karyotype of NB4 and also its p53 mutated status. In case chemotherapy drug resistant cell lines were published it should be clari®ed whether the resistance described is speci®c for a given drug, for a drug family, or is a multi-drug resistance (see in Maksumova et al., 2000; Naito et al., 2000) .
Garattini's group has recently selected a NB4 subclone (NB4-437r) showing a marked resistance to the synthetic RARg agonist CD437 (Ponzanelli et al., 2000) . Noteworthy, CD437 is a potent inducer of apoptotis for many cell types, including NB4. CD437 elicited apoptosis using a signaling pathway independent of RARg (Mologni et al., 1999) . This cell line should prove useful to characterize further the mechanism of action of CD437, possibly ending to a new apoptotic pathway. Since one can predict new cell line isolation in the ®eld of CD437 induced cell death, we propose to adopt immediately the above nomenclature system including the author's initial (NB4-G-437R).
This paper should be viewed as the ®rst stone in the building up a nomenclature for the NB4 cell line system. If this basis is accepted, further minor adaptations will have to be considered in the near future. On the other hand, if nothing is done to end the actual confusion with the names of NB4 subclones, it is now certain that investigators, authors and readers will suer greatly from our laxity.
